Home » Stocks » Praxis Precision Medicines

Praxis Precision Medicines, Inc. (PRAX)

Stock Price: $27.25 USD -0.55 (-1.98%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $27.45 +0.20 (0.73%) Oct 19, 7:58 PM

Stock Price Chart

Key Info

Market Cap 1.00B
Revenue (ttm) n/a
Net Income (ttm) -44.49M
Shares Out 36.74M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $27.25
Previous Close $27.80
Change ($) -0.55
Change (%) -1.98%
Day's Open 27.21
Day's Range 26.50 - 29.02
Day's Volume 285,112
52-Week Range 25.50 - 30.82

More Stats

Market Cap 1.00B
Enterprise Value 982.20M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 36.74M
Float 18.04M
EPS (basic) n/a
EPS (diluted) -1.21
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income -44.49M
Free Cash Flow n/a
Net Cash 19.23M
Net Cash / Share 0.52
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-35.79-22.72
Net Income-35.51-26.54
Shares Outstanding1.531.30
Earnings Per Share-26.60-22.52
Operating Cash Flow-33.42-20.72
Capital Expenditures-0.10-0.06
Free Cash Flow-33.52-20.78
Cash & Equivalents45.4218.55
Total Debt1.46-
Net Cash / Debt43.9618.55
Book Value-81.01-41.04
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Praxis Precision Medicines, Inc.
Country United States
Employees 42
CEO Marcio Souza

Stock Information

Ticker Symbol PRAX
Stock Exchange NASDAQ
Sector Health Technology
Industry Pharmaceuticals: Major
Unique Identifier NASDAQ: PRAX
IPO Date October 16, 2020


Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and disease. We are applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for severe pediatric epilepsies and more broadly for prevalent psychiatric diseases and neurologic disorders. We apply a deliberate and pragmatic precision approach, leveraging a suite of translational tools including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. We have three product candidates currently in clinical development. We intend to develop differentiated therapies that can deliver long-term benefits to human health by meaningfully impacting patients and society. Our insights into genetic mutations resulting in neuronal imbalance have enabled us to develop a pipeline addressing prevalent psychiatric and neurologic conditions and rare diseases, with the ability to expand into additional indications.